Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | SLC6A13 | Human | (+)-schisandrin B | multiple interactions | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of SLC6A13 mRNA] | CTD | PMID:31150632 | SLC6A13 | Human | (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC6A13 mRNA | CTD | PMID:22079256 | SLC6A13 | Human | (1->4)-beta-D-glucan | multiple interactions | ISO | Slc6a13 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of SLC6A13 mRNA | CTD | PMID:36331819 | SLC6A13 | Human | 1,2-dimethylhydrazine | increases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in increased expression of SLC6A13 mRNA | CTD | PMID:22206623 | SLC6A13 | Human | 17alpha-ethynylestradiol | multiple interactions | ISO | Slc6a13 (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of SLC6A13 mRNA | CTD | PMID:17942748 | SLC6A13 | Human | 17beta-estradiol | increases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Estradiol results in increased expression of SLC6A13 mRNA | CTD | PMID:32145629 | SLC6A13 | Human | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | Slc6a13 (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin binds to AHR protein] which results in decreased expression of SLC6A13 mRNA and [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of SLC6A13 mRNA | CTD | PMID:16214954 and PMID:17942748 | SLC6A13 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Slc6a13 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of SLC6A13 mRNA | CTD | PMID:21570461 | SLC6A13 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SLC6A13 mRNA | CTD | PMID:21215274 | SLC6A13 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SLC6A13 mRNA | CTD | PMID:18796159 and PMID:19770486 | SLC6A13 | Human | 2,3,7,8-Tetrachlorodibenzofuran | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | 2 more ... | CTD | PMID:32109520 | SLC6A13 | Human | 2,4-dibromophenyl 2,4,5-tribromophenyl ether | affects expression | ISO | Slc6a13 (Mus musculus) | 6480464 | 2 more ... | CTD | PMID:38648751 | SLC6A13 | Human | 2,4-dinitrotoluene | affects expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | 2 and 4-dinitrotoluene affects the expression of SLC6A13 mRNA | CTD | PMID:21346803 | SLC6A13 | Human | 2,6-dinitrotoluene | affects expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | 2 and 6-dinitrotoluene affects the expression of SLC6A13 mRNA | CTD | PMID:21346803 | SLC6A13 | Human | 2-palmitoylglycerol | increases expression | EXP | | 6480464 | 2-palmitoylglycerol results in increased expression of SLC6A13 mRNA | CTD | PMID:37199045 | SLC6A13 | Human | 3,3',4,4',5-pentachlorobiphenyl | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | 3 more ... | CTD | PMID:20959002 | SLC6A13 | Human | 3H-1,2-dithiole-3-thione | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | 1 and 2-dithiol-3-thione results in decreased expression of SLC6A13 mRNA | CTD | PMID:19162173 | SLC6A13 | Human | 4,4'-sulfonyldiphenol | increases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | bisphenol S results in increased expression of SLC6A13 mRNA | CTD | PMID:30951980 | SLC6A13 | Human | 4-hydroxyphenyl retinamide | decreases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | Fenretinide results in decreased expression of SLC6A13 mRNA | CTD | PMID:28973697 | SLC6A13 | Human | 6-propyl-2-thiouracil | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Propylthiouracil results in decreased expression of SLC6A13 mRNA | CTD | PMID:24780913 | SLC6A13 | Human | acetamide | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | acetamide results in decreased expression of SLC6A13 mRNA | CTD | PMID:31881176 | SLC6A13 | Human | aflatoxin B1 | decreases expression | EXP | | 6480464 | Aflatoxin B1 results in decreased expression of SLC6A13 mRNA | CTD | PMID:22100608 | SLC6A13 | Human | aflatoxin B1 | increases methylation | EXP | | 6480464 | Aflatoxin B1 results in increased methylation of SLC6A13 intron | CTD | PMID:30157460 | SLC6A13 | Human | alachlor | affects expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | alachlor affects the expression of SLC6A13 mRNA | CTD | PMID:19425180 | SLC6A13 | Human | ammonium chloride | affects expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Ammonium Chloride affects the expression of SLC6A13 mRNA | CTD | PMID:16483693 | SLC6A13 | Human | aristolochic acid A | increases expression | EXP | | 6480464 | aristolochic acid I results in increased expression of SLC6A13 mRNA | CTD | PMID:33212167 | SLC6A13 | Human | arsane | affects expression | EXP | | 6480464 | Arsenic affects the expression of SLC6A13 mRNA | CTD | PMID:18414638 | SLC6A13 | Human | arsenic atom | affects expression | EXP | | 6480464 | Arsenic affects the expression of SLC6A13 mRNA | CTD | PMID:18414638 | SLC6A13 | Human | benzo[a]pyrene | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Benzo(a)pyrene results in decreased expression of SLC6A13 mRNA | CTD | PMID:21839799 | SLC6A13 | Human | benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of SLC6A13 mRNA | CTD | PMID:32234424 | SLC6A13 | Human | benzo[a]pyrene | decreases methylation | EXP | | 6480464 | Benzo(a)pyrene results in decreased methylation of SLC6A13 5' UTR and Benzo(a)pyrene results in decreased methylation of SLC6A13 promoter | CTD | PMID:27901495 | SLC6A13 | Human | benzo[a]pyrene | decreases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased expression of SLC6A13 mRNA | CTD | PMID:19770486 more ... | SLC6A13 | Human | bisphenol A | affects expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | bisphenol A affects the expression of SLC6A13 mRNA | CTD | PMID:26950200 and PMID:30903817 | SLC6A13 | Human | bisphenol A | increases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of SLC6A13 mRNA | CTD | PMID:32145629 | SLC6A13 | Human | bisphenol A | increases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | bisphenol A results in increased expression of SLC6A13 mRNA | CTD | PMID:30951980 | SLC6A13 | Human | bisphenol A | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of SLC6A13 mRNA | CTD | PMID:25181051 more ... | SLC6A13 | Human | bisphenol F | increases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | bisphenol F results in increased expression of SLC6A13 mRNA | CTD | PMID:30951980 | SLC6A13 | Human | calcium silicate | increases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | calcium silicate results in increased expression of SLC6A13 mRNA | CTD | PMID:29279043 | SLC6A13 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of SLC6A13 mRNA | CTD | PMID:27392435 | SLC6A13 | Human | cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of SLC6A13 mRNA | CTD | PMID:27392435 | SLC6A13 | Human | clofibrate | decreases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | Clofibrate results in decreased expression of SLC6A13 mRNA | CTD | PMID:17585979 | SLC6A13 | Human | clofibric acid | affects expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Clofibric Acid affects the expression of SLC6A13 mRNA | CTD | PMID:17602206 | SLC6A13 | Human | coumarin | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | coumarin results in decreased expression of SLC6A13 mRNA | CTD | PMID:18480146 | SLC6A13 | Human | crocidolite asbestos | increases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | Asbestos and Crocidolite results in increased expression of SLC6A13 mRNA | CTD | PMID:29279043 | SLC6A13 | Human | dioxygen | decreases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | Oxygen deficiency results in decreased expression of SLC6A13 mRNA | CTD | PMID:24205000 | SLC6A13 | Human | diquat | increases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | Diquat results in increased expression of SLC6A13 mRNA | CTD | PMID:36851058 | SLC6A13 | Human | endosulfan | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Endosulfan results in decreased expression of SLC6A13 mRNA | CTD | PMID:29391264 | SLC6A13 | Human | epoxiconazole | decreases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | epoxiconazole results in decreased expression of SLC6A13 mRNA | CTD | PMID:35436446 | SLC6A13 | Human | ethyl methanesulfonate | increases expression | EXP | | 6480464 | Ethyl Methanesulfonate results in increased expression of SLC6A13 mRNA | CTD | PMID:23649840 | SLC6A13 | Human | flavonoids | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Flavonoids results in decreased expression of SLC6A13 mRNA | CTD | PMID:18035473 | SLC6A13 | Human | fluconazole | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Fluconazole results in decreased expression of SLC6A13 mRNA | CTD | PMID:16643972 | SLC6A13 | Human | flutamide | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Flutamide results in decreased expression of SLC6A13 mRNA | CTD | PMID:24136188 | SLC6A13 | Human | folic acid | decreases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | Folic Acid results in decreased expression of SLC6A13 protein | CTD | PMID:38272249 | SLC6A13 | Human | folic acid | multiple interactions | ISO | Slc6a13 (Mus musculus) | 6480464 | icariin inhibits the reaction [Folic Acid results in decreased expression of SLC6A13 protein] | CTD | PMID:38272249 | SLC6A13 | Human | furan | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | furan results in decreased expression of SLC6A13 mRNA | CTD | PMID:25539665 | SLC6A13 | Human | gamma-aminobutyric acid | increases export | EXP | | 6480464 | SLC6A13 results in increased export of gamma-Aminobutyric Acid | CTD | PMID:21748804 | SLC6A13 | Human | graphite | affects expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Graphite affects the expression of SLC6A13 mRNA | CTD | PMID:29933104 | SLC6A13 | Human | GW 4064 | increases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | GW 4064 results in increased expression of SLC6A13 mRNA | CTD | PMID:26655953 | SLC6A13 | Human | hydralazine | multiple interactions | EXP | | 6480464 | [Hydralazine co-treated with Valproic Acid] results in increased expression of SLC6A13 mRNA | CTD | PMID:17183730 | SLC6A13 | Human | icariin | multiple interactions | ISO | Slc6a13 (Mus musculus) | 6480464 | icariin inhibits the reaction [Folic Acid results in decreased expression of SLC6A13 protein] | CTD | PMID:38272249 | SLC6A13 | Human | leflunomide | increases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | leflunomide results in increased expression of SLC6A13 mRNA | CTD | PMID:24136188 | SLC6A13 | Human | Licochalcone B | increases expression | EXP | | 6480464 | licochalcone B results in increased expression of SLC6A13 mRNA | CTD | PMID:33647349 | SLC6A13 | Human | lipopolysaccharide | multiple interactions | EXP | | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of SLC6A13 mRNA | CTD | PMID:35811015 | SLC6A13 | Human | methamphetamine | multiple interactions | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | [Methamphetamine co-treated with SCH 23390] results in decreased expression of SLC6A13 mRNA | CTD | PMID:19564919 | SLC6A13 | Human | methamphetamine | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Methamphetamine results in decreased expression of SLC6A13 mRNA | CTD | PMID:19564919 | SLC6A13 | Human | methidathion | decreases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | methidathion results in decreased expression of SLC6A13 mRNA | CTD | PMID:34813904 | SLC6A13 | Human | methyl methanesulfonate | increases expression | EXP | | 6480464 | Methyl Methanesulfonate results in increased expression of SLC6A13 mRNA | CTD | PMID:23649840 | SLC6A13 | Human | Muraglitazar | increases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | muraglitazar results in increased expression of SLC6A13 mRNA | CTD | PMID:21515302 | SLC6A13 | Human | N-nitrosodiethylamine | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Diethylnitrosamine results in decreased expression of SLC6A13 mRNA | CTD | PMID:19638242 | SLC6A13 | Human | N-nitrosodiethylamine | multiple interactions | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | [Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of SLC6A13 mRNA | CTD | PMID:28943392 | SLC6A13 | Human | N-Nitrosopyrrolidine | decreases expression | EXP | | 6480464 | N-Nitrosopyrrolidine results in decreased expression of SLC6A13 mRNA | CTD | PMID:32234424 | SLC6A13 | Human | nitrofen | increases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | nitrofen results in increased expression of SLC6A13 mRNA | CTD | PMID:33484710 | SLC6A13 | Human | O-methyleugenol | decreases expression | EXP | | 6480464 | methyleugenol results in decreased expression of SLC6A13 mRNA | CTD | PMID:32234424 | SLC6A13 | Human | paracetamol | affects expression | ISO | Slc6a13 (Mus musculus) | 6480464 | Acetaminophen affects the expression of SLC6A13 mRNA | CTD | PMID:17562736 | SLC6A13 | Human | perfluorohexanesulfonic acid | decreases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | perfluorohexanesulfonic acid results in decreased expression of SLC6A13 mRNA | CTD | PMID:37315490 | SLC6A13 | Human | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Slc6a13 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of SLC6A13 mRNA | CTD | PMID:36331819 | SLC6A13 | Human | phenobarbital | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Phenobarbital results in decreased expression of SLC6A13 mRNA | CTD | PMID:19162173 | SLC6A13 | Human | pirinixic acid | decreases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | pirinixic acid results in decreased expression of SLC6A13 mRNA | CTD | PMID:23811191 | SLC6A13 | Human | potassium chromate | increases expression | EXP | | 6480464 | potassium chromate(VI) results in increased expression of SLC6A13 mRNA | CTD | PMID:22079256 | SLC6A13 | Human | potassium chromate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC6A13 mRNA | CTD | PMID:22079256 | SLC6A13 | Human | pregnenolone 16alpha-carbonitrile | increases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Pregnenolone Carbonitrile results in increased expression of SLC6A13 mRNA | CTD | PMID:19162173 | SLC6A13 | Human | resveratrol | multiple interactions | EXP | | 6480464 | [Plant Extracts co-treated with Resveratrol] results in decreased expression of SLC6A13 mRNA | CTD | PMID:23557933 | SLC6A13 | Human | rotenone | increases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Rotenone results in increased expression of SLC6A13 mRNA | CTD | PMID:28374803 | SLC6A13 | Human | rotenone | decreases expression | EXP | | 6480464 | Rotenone results in decreased expression of SLC6A13 mRNA | CTD | PMID:29955902 | SLC6A13 | Human | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | EXP | | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of SLC6A13 mRNA | CTD | PMID:35811015 | SLC6A13 | Human | S-(1,2-dichlorovinyl)-L-cysteine | increases expression | EXP | | 6480464 | S-(1 and 2-dichlorovinyl)cysteine results in increased expression of SLC6A13 mRNA | CTD | PMID:35811015 | SLC6A13 | Human | SCH 23390 | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | SCH 23390 results in decreased expression of SLC6A13 mRNA | CTD | PMID:19564919 | SLC6A13 | Human | SCH 23390 | multiple interactions | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | [Methamphetamine co-treated with SCH 23390] results in decreased expression of SLC6A13 mRNA | CTD | PMID:19564919 | SLC6A13 | Human | silver atom | increases expression | EXP | | 6480464 | Silver results in increased expression of SLC6A13 mRNA | CTD | PMID:26014281 | SLC6A13 | Human | silver(0) | increases expression | EXP | | 6480464 | Silver results in increased expression of SLC6A13 mRNA | CTD | PMID:26014281 | SLC6A13 | Human | sodium arsenite | increases expression | EXP | | 6480464 | sodium arsenite results in increased expression of SLC6A13 mRNA | CTD | PMID:38568856 | SLC6A13 | Human | succimer | multiple interactions | ISO | Slc6a13 (Mus musculus) | 6480464 | [Succimer binds to Magnetite Nanoparticles] which results in decreased expression of SLC6A13 mRNA | CTD | PMID:21641980 and PMID:23086747 | SLC6A13 | Human | Tesaglitazar | increases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | tesaglitazar results in increased expression of SLC6A13 mRNA | CTD | PMID:21515302 | SLC6A13 | Human | testosterone | increases expression | EXP | | 6480464 | Testosterone results in increased expression of SLC6A13 mRNA | CTD | PMID:33359661 | SLC6A13 | Human | tetrachloromethane | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Carbon Tetrachloride results in decreased expression of SLC6A13 mRNA and Carbon Tetrachloride results in decreased expression of SLC6A13 protein | CTD | PMID:17544377 and PMID:31150632 | SLC6A13 | Human | tetrachloromethane | decreases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | Carbon Tetrachloride results in decreased expression of SLC6A13 mRNA | CTD | PMID:31919559 | SLC6A13 | Human | tetrachloromethane | multiple interactions | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of SLC6A13 mRNA] | CTD | PMID:31150632 | SLC6A13 | Human | Theaflavin 3,3'-digallate | affects expression | EXP | | 6480464 | theaflavin-3 and 3'-digallate affects the expression of SLC6A13 mRNA | CTD | PMID:34925699 | SLC6A13 | Human | thioacetamide | multiple interactions | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | [Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of SLC6A13 mRNA | CTD | PMID:28943392 | SLC6A13 | Human | thioacetamide | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Thioacetamide results in decreased expression of SLC6A13 mRNA | CTD | PMID:34492290 | SLC6A13 | Human | thiram | increases expression | EXP | | 6480464 | Thiram results in increased expression of SLC6A13 mRNA | CTD | PMID:38568856 | SLC6A13 | Human | titanium dioxide | decreases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | titanium dioxide results in decreased expression of SLC6A13 mRNA | CTD | PMID:23557971 | SLC6A13 | Human | toluene | affects expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | Toluene affects the expression of SLC6A13 mRNA | CTD | PMID:18653662 | SLC6A13 | Human | tremolite asbestos | increases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | tremolite results in increased expression of SLC6A13 mRNA | CTD | PMID:29279043 | SLC6A13 | Human | triadimefon | decreases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | triadimefon results in decreased expression of SLC6A13 mRNA | CTD | PMID:16643972 | SLC6A13 | Human | triclosan | increases expression | EXP | | 6480464 | Triclosan results in increased expression of SLC6A13 mRNA | CTD | PMID:30510588 | SLC6A13 | Human | trimellitic anhydride | decreases expression | ISO | Slc6a13 (Mus musculus) | 6480464 | trimellitic anhydride results in decreased expression of SLC6A13 mRNA | CTD | PMID:19042947 | SLC6A13 | Human | troglitazone | increases expression | ISO | Slc6a13 (Rattus norvegicus) | 6480464 | troglitazone results in increased expression of SLC6A13 mRNA | CTD | PMID:21515302 | SLC6A13 | Human | valproic acid | multiple interactions | EXP | | 6480464 | [Hydralazine co-treated with Valproic Acid] results in increased expression of SLC6A13 mRNA | CTD | PMID:17183730 | SLC6A13 | Human | zinc atom | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of SLC6A13 mRNA | CTD | PMID:18593933 | SLC6A13 | Human | zinc(0) | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of SLC6A13 mRNA | CTD | PMID:18593933 | |